Signs of broader recovery are emerging in the South Korean biotech sector following the landmark US approval of Yuhan Corporation's novel lung cancer drug Lazcluze (lazertinib) in August through licensee Johnson & Johnson.
The oral EGFR tyrosine kinase inhibitor (TKI) was approved in combination with J&J's bispecific antibody Rybrevant (amivantamab) as a chemotherapy-free regimen in patients with first-line, non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations. It marked the first time for a Korea-originated oncology drug to receive a nod from the Food and Drug Administration